[go: up one dir, main page]

CL2021002389A1 - Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y uso del agente para tratar o prevenir trastornos cognitivos. (divisional de la solicitud 201902296) - Google Patents

Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y uso del agente para tratar o prevenir trastornos cognitivos. (divisional de la solicitud 201902296)

Info

Publication number
CL2021002389A1
CL2021002389A1 CL2021002389A CL2021002389A CL2021002389A1 CL 2021002389 A1 CL2021002389 A1 CL 2021002389A1 CL 2021002389 A CL2021002389 A CL 2021002389A CL 2021002389 A CL2021002389 A CL 2021002389A CL 2021002389 A1 CL2021002389 A1 CL 2021002389A1
Authority
CL
Chile
Prior art keywords
treat
cognitive disorders
prevent cognitive
divisional
agent
Prior art date
Application number
CL2021002389A
Other languages
English (en)
Inventor
Hiroshi Eguchi
Takashi Murakami
Naoko Namiki
Akira Tanokura
Jeanne E Baker
Batteur Sophie Parmentier
Angela Marie Jablonski
Daniel Steven Malashock
Carl Mieczkowski
Gopalan Raghunathan (Raghu)
Original Assignee
Merck Sharp & Dohme
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Teijin Pharma Ltd filed Critical Merck Sharp & Dohme
Publication of CL2021002389A1 publication Critical patent/CL2021002389A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona anticuerpos y composiciones de anticuerpos humanizados que se unen a la proteína tau que está fosforilada en la serina en la posición 413 y su uso.
CL2021002389A 2017-02-27 2021-09-13 Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y uso del agente para tratar o prevenir trastornos cognitivos. (divisional de la solicitud 201902296) CL2021002389A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017035594A JP2018139530A (ja) 2017-02-27 2017-02-27 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤

Publications (1)

Publication Number Publication Date
CL2021002389A1 true CL2021002389A1 (es) 2022-04-22

Family

ID=62025891

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2019002296A CL2019002296A1 (es) 2017-02-27 2019-08-13 Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y uso del agente para tratar o prevenir trastornos cognitivos.
CL2021002389A CL2021002389A1 (es) 2017-02-27 2021-09-13 Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y uso del agente para tratar o prevenir trastornos cognitivos. (divisional de la solicitud 201902296)
CL2024000339A CL2024000339A1 (es) 2017-02-27 2024-02-02 Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2019002296A CL2019002296A1 (es) 2017-02-27 2019-08-13 Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y uso del agente para tratar o prevenir trastornos cognitivos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2024000339A CL2024000339A1 (es) 2017-02-27 2024-02-02 Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo.

Country Status (26)

Country Link
US (3) US10556950B2 (es)
EP (1) EP3585810B1 (es)
JP (4) JP2018139530A (es)
KR (1) KR102701634B1 (es)
CN (2) CN110382528A (es)
AR (2) AR110875A1 (es)
AU (1) AU2018224390C1 (es)
BR (1) BR112019016490A2 (es)
CA (1) CA3052538A1 (es)
CL (3) CL2019002296A1 (es)
CO (1) CO2019008786A2 (es)
CR (1) CR20190363A (es)
DO (1) DOP2019000215A (es)
EA (1) EA201991726A1 (es)
GE (1) GEP20227392B (es)
IL (1) IL267945B2 (es)
JO (1) JOP20180014A1 (es)
MA (1) MA47608A (es)
MX (2) MX2019009945A (es)
MY (1) MY193821A (es)
NI (1) NI201900086A (es)
PE (2) PE20241514A1 (es)
PH (1) PH12019501929A1 (es)
SG (2) SG11201907548PA (es)
TW (2) TWI848904B (es)
WO (2) WO2018154392A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2657438C2 (ru) * 2012-05-31 2018-06-13 Осака Сити Юниверсити Терапевтическое средство или профилактическое средство против деменции
CN110520440A (zh) 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
TWI853617B (zh) 2017-10-16 2024-08-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
US20210355199A1 (en) 2018-06-28 2021-11-18 University Of Virginia Patent Foundation Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling
US12365724B2 (en) * 2018-12-10 2025-07-22 New York University Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof
EP3924464A4 (en) 2019-02-11 2022-11-23 University of Virginia Patent Foundation SELECTION AND BLOCKING OF MALE AND FEMALE GAMETES SUITABLE FOR FERTILIZATION
AU2020234718A1 (en) 2019-03-13 2023-05-18 Tearsolutions, Inc. Compositions and methods for promoting islet viability and enhancing insulin secretion
CA3148740A1 (en) * 2019-08-06 2021-02-11 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
CN115605594A (zh) * 2020-06-02 2023-01-13 帝人制药株式会社（Jp） 抗igf-1受体人源化抗体
CN116723856A (zh) * 2020-06-25 2023-09-08 默沙东有限责任公司 靶向丝氨酸413处磷酸化的tau的高亲和力抗体
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN115322255B (zh) * 2022-04-25 2025-03-07 上海药明生物医药有限公司 一种优化的Fc变体及其应用
JP2025535203A (ja) 2022-09-15 2025-10-23 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN119080924B (zh) * 2024-07-04 2025-02-25 上海交通大学医学院附属第九人民医院 一种单克隆免疫球蛋白及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS587390B2 (ja) 1975-03-11 1983-02-09 ツキシマキカイ カブシキガイシヤ ア−クヨウセツホウホウ
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
JP3587390B2 (ja) 1994-03-17 2004-11-10 タカラバイオ株式会社 リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法
US7657380B2 (en) 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
WO2005022156A1 (ja) 2003-08-29 2005-03-10 Reverse Proteomics Research Institute Co., Ltd. タンパク質の固定化方法
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US9304138B2 (en) * 2010-10-07 2016-04-05 Katholieke Universiteit Leuven Pharmaceutical composition
PT2627672T (pt) * 2010-10-11 2018-11-16 Univ Zuerich Anticorpos anti-tau humanos
UA114902C2 (uk) 2011-12-20 2017-08-28 Янссен Байотек, Інк. Виділене антитіло, яке зв'язує парний спіральний філамент-тау (псф-тау), та фармацевтична композиція, що містить таке антитіло
RU2657438C2 (ru) * 2012-05-31 2018-06-13 Осака Сити Юниверсити Терапевтическое средство или профилактическое средство против деменции
AU2013302540B2 (en) * 2012-08-16 2018-02-15 Ipierian, Inc. Methods of treating a tauopathy
AU2013361107B2 (en) 2012-12-21 2018-08-23 Biogen International Neuroscience Gmbh Human anti-tau antibodies
RS60883B1 (sr) 2013-06-10 2020-11-30 Ipierian Inc Metodi lečenja tauopatije
SG11201605044RA (en) 2013-12-20 2016-07-28 Hoffmann La Roche HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TW202136296A (zh) * 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
MX2017003478A (es) 2014-11-05 2018-02-01 Genentech Inc Anticuerpos anti-fgfr2/3 y metodos para su uso.
WO2016112078A2 (en) 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
CN107849105B (zh) 2015-07-06 2021-09-17 Ucb生物制药有限责任公司 Tau结合抗体
WO2017005734A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
JP2018139530A (ja) * 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤

Also Published As

Publication number Publication date
AU2018224390B2 (en) 2024-10-31
EA201991726A1 (ru) 2020-01-30
MA47608A (fr) 2020-01-01
MX2019009945A (es) 2019-11-05
CO2019008786A2 (es) 2019-08-20
KR102701634B1 (ko) 2024-08-30
PH12019501929A1 (en) 2020-06-29
NI201900086A (es) 2019-10-08
JP2020508666A (ja) 2020-03-26
JP2024170459A (ja) 2024-12-10
MX2023013246A (es) 2023-11-21
EP3585810B1 (en) 2025-11-26
BR112019016490A2 (pt) 2020-04-07
CN111320695A (zh) 2020-06-23
WO2018154390A1 (en) 2018-08-30
CA3052538A1 (en) 2018-08-30
JOP20180014A1 (ar) 2019-01-30
KR20190122674A (ko) 2019-10-30
DOP2019000215A (es) 2019-09-30
IL267945B1 (en) 2025-06-01
AR117952A2 (es) 2021-09-08
SG10201913419TA (en) 2020-03-30
EP3585810A1 (en) 2020-01-01
IL267945A (en) 2019-09-26
US20200223916A1 (en) 2020-07-16
TWI848904B (zh) 2024-07-21
CL2019002296A1 (es) 2019-11-29
GEP20227392B (en) 2022-06-27
PE20191614A1 (es) 2019-11-05
US20210380677A1 (en) 2021-12-09
CL2024000339A1 (es) 2024-08-16
CN110382528A (zh) 2019-10-25
JP2018139530A (ja) 2018-09-13
US10894829B2 (en) 2021-01-19
MY193821A (en) 2022-10-27
AU2018224390A1 (en) 2019-07-11
CR20190363A (es) 2019-11-05
WO2018154392A1 (en) 2018-08-30
PE20241514A1 (es) 2024-07-19
IL267945B2 (en) 2025-10-01
CN111320695B (zh) 2021-09-03
AR110875A1 (es) 2019-05-08
AU2018224390C1 (en) 2025-04-17
US11739143B2 (en) 2023-08-29
JP7165996B2 (ja) 2022-11-07
US10556950B2 (en) 2020-02-11
US20180346564A1 (en) 2018-12-06
TW202506718A (zh) 2025-02-16
TW201843179A (zh) 2018-12-16
JP2023002670A (ja) 2023-01-10
SG11201907548PA (en) 2019-09-27

Similar Documents

Publication Publication Date Title
CL2021002389A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y uso del agente para tratar o prevenir trastornos cognitivos. (divisional de la solicitud 201902296)
CL2019001411A1 (es) Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817)
CL2019003114A1 (es) Anticuerpos anti–tau y métodos de uso (divisional solicitud 201703063)
CL2021000517A1 (es) Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
CL2018002694A1 (es) Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112)
UY38407A (es) Anticuerpos estabilizadores de trem2
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
JOP20200132A1 (ar) صيغة مجففة بالتبريد من جسم مضاد أحادي النسيلة ضد ترانس ثيرتين
CR20170600A (es) Anticuerpos del factor x1 y métodos de uso
MX2022010229A (es) Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
JOP20180117B1 (ar) أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها
EA201990400A1 (ru) Соединения и композиции и их применение
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
CL2021000849A1 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos (divisional de la solicitud no. 201900999)
MX2024005841A (es) Moleculas de union a cd32b x cd79b para usarse como medicamentos para el tratamiento de enfermedades o trastornos inflamatorios y para reducir las respuestas inmunitarias.
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
MX2019010060A (es) Composiciones y metodo para tratar cancer.
MX391162B (es) Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5
EA202092123A1 (ru) Антитела против клаудина 18.2 и их применения
AR117649A1 (es) Anticuerpos estabilizadores de trem2
EA202090330A1 (ru) Композиции и способы лечения расстройств, связанных со стрессом
EA202090891A1 (ru) Молекулы антител против cd138 и их применение